US 2004/0176336 A1 · Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium

Abstract

The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer. Enhanced HRT and OCP regimens and formulations are also disclosed.

Claims1

Dependent claims

A hormonal regimen wherein at least one of the daily dosages comprises at least 0.5 mg of norgestimate and an estrogen component which does not exceed 35 mcg EE equivalent.

Dependencies are inferred from the claim text.

Facts

Application

10/802,273Filed 17 Mar 2004

Priority

21 Mar 2000

Published

9 Sep 2004

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 31/56
Medicinal preparations containing organic active ingredients: compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives…
A61K 31/57
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids: substituted in position 17 beta by a chain…
A61K 31/59
Medicinal preparations containing organic active ingredients: compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
A61P 15/18
Drugs for genital or sexual disorders ; Contraceptives: feminine contraceptives

Family

Application09/528,963Continuation in part · filed 21 Mar 2000

Application09/532,340Continuation in part · filed 21 Mar 2000

Application09/672,735Continuation in part · filed 28 Sep 2000

Application09/798,453Continuation in part · filed 2 Mar 2001

Application10/802,273Continuation in part · filed 17 Mar 2004

US 2001/0044431 A1Published application

US 2003/0125229 A1Published application

US 6,511,970 B1Related patent

US 6,765,002 B2Related patent

US 2004/0176336 A1This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer. Enhanced HRT and OCP regimens and formulations are also disclosed.

Facts

Application

10/802,273Filed 17 Mar 2004

Priority

21 Mar 2000

Published

9 Sep 2004

Term ends

Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 31/56
Medicinal preparations containing organic active ingredients: compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives…
A61K 31/57
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids: substituted in position 17 beta by a chain…
A61K 31/59
Medicinal preparations containing organic active ingredients: compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
A61P 15/18
Drugs for genital or sexual disorders ; Contraceptives: feminine contraceptives

Family

Application09/528,963Continuation in part · filed 21 Mar 2000

Application09/532,340Continuation in part · filed 21 Mar 2000

Application09/672,735Continuation in part · filed 28 Sep 2000

Application09/798,453Continuation in part · filed 2 Mar 2001

Application10/802,273Continuation in part · filed 17 Mar 2004

US 2001/0044431 A1Published application

US 2003/0125229 A1Published application

US 6,511,970 B1Related patent

US 6,765,002 B2Related patent

US 2004/0176336 A1This patent

From the US filing history. Foreign family members aren’t listed.

Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium

Life of this patent

Abstract

Claims1

Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium

Life of this patent

Abstract

Claims1